Agarwal N et al. CYCLONE 1: A Phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy. ASCO 2021;Abstract TPS5086.
Bogemann M et al. Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer stratified by prostate-specific antigen doubling time: Planned subgroup analysis of the phase 3 ARAMIS trial. Eur Urol 2022;[Online ahead of print]. Abstract
Ciccarese C et al. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. Eur J Cancer 2022;173:276-84. Abstract
Chowdhury S et al. Apalutamide compared with darolutamide for the treatment of non-metastatic castration-resistant prostate cancer: Efficacy and tolerability in a matching-adjusted indirect comparison. Adv Ther 2022;39(1):518-31. Abstract
Colombo E et al. ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC). ASCO 2021;Abstract 5046.
Fizazi K et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, phase 3 study with a 2 x 2 factorial design. Lancet 2022;399(10336):1695-707. Abstract
Gillessen S et al. Management of patients with advanced prostate cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol 2022;82(1):115-41. Abstract
Giraudet A-L et al. PSMA targeting in metastatic castration-resistant prostate cancer: Where are we and where are we going? Ther Adv Med Oncol 2021;13:17588359211053898. Abstract
Haresh KP et al. A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE). ASCO 2022;Abstract TPS200.
Hussain M et al. Evolving role of prostate-specific membrane antigen-positron emission tomography in metastatic hormone-sensitive prostate cancer: More questions than answers? J Clin Oncol 2022;40(26):3011-6. Abstract
Kartolo A et al. Management of metastatic hormone-sensitive prostate cancer: Is docetaxel needed? J Clin Oncol 2022;40(31):3573-6. Abstract
Mehlhaff B et al. Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study. AUA 2022;Abstract MP27-16.
Parker CC et al. Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). ESMO 2022;Abstract LBA9.
Saad F et al. Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial. ASCO 2022;Abstract 5078.
Smith MR et al. Blood biomarker landscape in patients with high-risk nonmetastatic castration-resistant prostate cancer treated with apalutamide and androgen-deprivation therapy as they progress to metastatic disease. Clin Cancer Res 2021;27(16):4539-48. Abstract
Smith MR et al. CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer. ASCO GU 2022;Abstract TPS198.
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386(12):1132-42. Abstract
Smith MR et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: A patient and caregiver perspective and plain language summary of the ARSENS trial. Future Oncol 2022;18(21):2585-97. Abstract
Terrisse S et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother Cancer 2022;10(3):e004191. Abstract